

31st July, 2017

The Dy. General Manager (Listing Dept.)
BSE Limited
Corporate Relationship Dept.,
1st Floor, New Trading Ring,
P. J. Towers, Dalal Street, Fort,
Mumbai - 400 001
(BSE Scrip Code: 500420)

The Manager – Listing Dept.,
National Stock Exchange of India Ltd.,
Exchange Plaza, 5<sup>th</sup> Floor,
Plot No. C/1, O. Block,
Bandra - Kurla Complex, Bandra (E),
Mumbai – 400 051
(NSE Scrip Code: TORNTPHARM)

Dear Sir,

Re: Proceedings of 44th Annual General Meeting of the Company held on 31st July, 2017

In terms of Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), we hereby inform you that the following business was transacted at the 44<sup>th</sup> Annual General Meeting (AGM) of the Company held on 31<sup>st</sup> July, 2017:

- 1. Approval and adoption of Standalone and Consolidated Financial Statements as at 31st March, 2017, including the Audited Balance Sheet as at 31st March, 2017, the Statement of Profit and Loss for the year ended on that date and reports of the Board of Directors and Auditors thereon.
- 2. Confirmation of payment of interim dividend of ₹ 10/- per equity share and declaration of ₹ 4/- per equity share as final dividend for the financial year ended 31st March, 2017.
- 3. Re-appointment of Dr. Chaitanya Dutt (holding DIN 00110312) who retired by rotation and was eligible for re-appointment.
- 4. Appointment of BSR & Co., LLP, Chartered Accountants (Firm Registration No. 101248W/W-100022) as Statutory Auditors of the Company to hold office from the conclusion of this 44<sup>th</sup> AGM until the conclusion of the 49<sup>th</sup> AGM subject to ratification by members every year and to authorize Board to fix their remuneration.
- 5. Ratification of remuneration of cost auditors of the company for the year 2017-18.
- 6. Re-appointment of Dr. Chaitanya Dutt (holding DIN 00110312) as Whole Time Director and fixation of his remuneration.
- 7. Issuance of Redeemable Non-Convertible Debentures / Bonds by way of Private Placement.





The above business was transacted by e-voting and Poll at the meeting as required under Companies Act, 2013 and Listing Regulations. Results of the passing of above resolutions as required under Regulation 44(3) of Listing Regulations will be disclosed to the Stock Exchange separately.

Kindly take note of the above.

Yours Sincerely,

For TORRENT PHARMACEUTICALS LIMITED

MAHESH AGRAWAL

VP (LEGAL) & COMPANY SECRETARY